Medicamen Biotech consolidated net profit rises 59.50% in the March 2026 quarter
(27 May 2026)

Back
Net profit of Medicamen Biotech rose 59.50% to Rs 3.86 crore in the quarter ended March 2026 as against Rs 2.42 crore during the previous quarter ended March 2025. Sales rose 104.83% to Rs 60.65 crore in the quarter ended March 2026 as against Rs 29.61 crore during the previous quarter ended March 2025.

For the full year,net profit rose 35.58% to Rs 9.64 crore in the year ended March 2026 as against Rs 7.11 crore during the previous year ended March 2025. Sales rose 21.67% to Rs 197.77 crore in the year ended March 2026 as against Rs 162.55 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales60.6529.61 105 197.77162.55 22
OPM %8.97-5.44 -9.918.53 -
PBDT6.792.97 129 19.2016.95 13
PBT5.062.49 103 11.989.88 21
NP3.862.42 60 9.647.11 36

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew